

# **MEDICAL LABORATORY EVALUATION**

## **PARTICIPANT SUMMARY**

**2 • 0 • 0 • 6**

**Please see the corresponding US participant summary for any statistics not represented in this supplement.**



Total Commitment to Education and Service  
Provided by ACP Services, Inc.

**International Data Supplement  
MLE – M1**

# Table of Contents

<b>2006 Evaluation Criteria</b> .....	<b>3</b>
<b>Coagulation</b>	
<b>Prothrombin Time</b> .....	4
International Normalized Ratio (INR) .....	5
<b>Activated Partial Thromboplastin Time</b> .....	6
<b>Fibrinogen</b> .....	7
<b>Urinalysis</b>	
<b>Urinalysis Dipstick</b> .....	8
Specific Gravity .....	8
pH .....	8
Protein .....	8
Glucose or Reducing Substance .....	9
Ketones.....	9
Bilirubin .....	10
Urobilinogen.....	10
Blood or Hemoglobin .....	11
Leukocyte Esterase .....	11
Nitrite .....	12
Microalbumin (Dipstick Only) .....	12
<b>Urine hcG</b> .....	12
<b>Microbiology</b>	
<b>Antimicrobial Susceptibility Testing</b> .....	13
<b>Parasitology (PA Specimens)</b> .....	14
<b>Parasitology (FP Specimens)</b> .....	15
<b>Immunology</b>	
<b>Syphilis Serology</b> .....	16
VDRL Slide .....	16
VDRL Slide (Titer).....	17
MHA-TP .....	17
FTA-ABS.....	17
RPR .....	18
RPR (Titer).....	18
<b>Viral Markers</b> .....	19
Anti-HBc.....	19
Anti-HIV .....	19
HAV .....	20
HBeAg .....	20
HBsAb.....	21
HBsAg.....	21
HCV .....	22
<b>Chemistry</b>	
<b>Total Bilirubin</b> .....	23
<b>Neonatal Bilirubin</b> .....	23
<b>Blood Gases</b> .....	24

## 2006 Evaluation Criteria

The evaluation criteria used in the 2006 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	$\pm$ 15 percent
Bilirubin, Neonatal (Total)	$\pm$ 0.4 mg/dL or 20% *
Bilirubin, Total	$\pm$ 0.4 mg/dL or 20% *
Calcium, Ionized	$\pm$ 3 SD
Chloride	$\pm$ 5%
Fibrinogen	$\pm$ 20 percent
pCO <sub>2</sub>	$\pm$ 5 mmHg or 8% *
pH	$\pm$ 0.04
pO <sub>2</sub>	$\pm$ 3 SD
Potassium	$\pm$ 0.5 mmol/L
Prothrombin Time	$\pm$ 15 percent
Sodium	$\pm$ 4.0 mmol/L
Specific Gravity	$\pm$ 0.010

# Coagulation

## PROTHROMBIN TIME (seconds)

<u>Reagent/Instruments</u>	Specimen CG-1					Specimen CG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method Dade Innovin	71	12.50	1.32	10.5	12.8	72	54.92	12.70	23.1	60.0
All Coagulation Instruments Dade Thromborel S	10	10.44	0.53	5.1	10.7	10	48.84	2.98	6.1	49.3
All Coagulation Instruments Diag Stago STA Neoplastine CL+	8	12.21	0.72	5.9	12.4	9	60.11	18.51	30.8	64.4
RAL Clot-SP All Coagulation Instruments	10	13.83	0.34	2.5	14.0	10	57.29	2.57	4.5	57.0
Method IL TEST PT-FIB HS PLUS	13	13.68	0.43	3.1	13.6	13	59.12	4.55	7.7	57.9
bioMerieux Thrombotimer All Coagulation Instruments	6	14.53	0.32	2.2	14.6	6	72.10	7.68	10.7	72.8
IL TEST PT-FIB HS IL ACL, all models	14	12.50	0.77	6.2	12.4	14	42.86	9.29	21.7	41.4
IL TEST PT-FIB Recombinant IL ACL, all models	13	12.35	1.09	8.8	12.0	14	67.06	7.58	11.3	66.2
	Specimen CG-3					Specimen CG-4				
All Method Dade Innovin	70	15.74	1.84	11.7	16.3	71	19.71	3.11	15.8	20.7
All Coagulation Instruments Dade Thromborel S	10	12.96	0.65	5.0	13.2	10	16.76	0.42	2.5	16.7
All Coagulation Instruments Diag Stago STA Neoplastine CL+	8	15.20	1.31	8.6	15.3	9	20.26	2.20	10.8	20.3
RAL Clot-SP All Coagulation Instruments	10	17.59	0.54	3.1	17.8	10	20.74	0.46	2.2	20.8
IL TEST PT-FIB HS PLUS bioMerieux Thrombotimer	13	17.44	0.59	3.4	17.5	13	20.87	0.52	2.5	20.8
All Coagulation Instruments IL TEST PT-FIB HS	6	19.02	0.70	3.7	19.2	6	24.07	1.36	5.7	24.5
IL ACL, all models IL TEST PT-FIB Recombinant	16	19.36	0.72	3.7	19.2	16	24.47	1.53	6.2	24.5
IL ACL, all models	13	15.39	1.06	6.9	15.4	12	16.94	1.46	8.6	16.9
IL TEST PT-FIB Recombinant IL ACL, all models	13	16.24	1.74	10.7	15.6	14	23.26	3.20	13.8	23.5
	Specimen CG-5									
All Method Dade Innovin	69	12.23	1.24	10.1	12.6					
All Coagulation Instruments Dade Thromborel S	9	10.44	0.38	3.7	10.5					
All Coagulation Instruments Diag Stago STA Neoplastine CL+	9	11.42	1.05	9.2	11.4					
RAL Clot-SP All Coagulation Instruments	10	13.07	0.41	3.1	13.1					
IL TEST PT-FIB HS PLUS bioMerieux Thrombotimer	12	12.98	0.48	3.7	13.1					
All Coagulation Instruments IL TEST PT-FIB HS	6	13.63	0.22	1.6	13.7					
IL ACL, all models IL TEST PT-FIB Recombinant	16	14.02	0.48	3.4	14.1					
IL ACL, all models	13	12.51	1.01	8.1	12.3					
IL TEST PT-FIB Recombinant IL ACL, all models	13	12.08	0.88	7.3	11.7					







# Urinalysis

## URINALYSIS DIPSTICK–SPECIFIC GRAVITY

### Specimen UA-1

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	70	1.0176	0	0	1.015
Bayer Clinitek 50	3	-	-	-	1.015
Bayer Clinitek 500	14	1.0189	0	0	1.020
Bayer Clinitek Atlas	4	-	-	-	1.025
Bayer Reagent Strips	3	-	-	-	1.010
Roche (BMC) Chemstrips	17	1.0154	0	0	1.015
Roche (BMC) Criterion Analyzer	3	-	-	-	1.015
Roche Urisys	4	-	-	-	1.023
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	1.015
UriScan Reagent Strips	7	1.0179	0	0	1.020

## URINALYSIS DIPSTICK–pH

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHOD	-	-	-	-	-	-	5	25	42	-	-
Arkray Aution Jet	-	-	-	-	-	-	-	2	-	-	-
Arkray Aution Sticks	-	-	-	-	-	-	-	2	-	-	-
Bayer Clinitek 50	-	-	-	-	-	-	-	2	1	-	-
Bayer Clinitek 500	-	-	-	-	-	-	1	3	11	-	-
Bayer Clinitek Atlas	-	-	-	-	-	-	-	4	-	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	1	-	-	-
Bayer Reagent Strips	-	-	-	-	-	-	-	3	1	-	-
Roche (BMC) Chemstrips	-	-	-	-	-	-	2	-	15	-	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	-	-	-	-	-	2	-	-
Roche Mditron	-	-	-	-	-	-	-	-	2	-	-
Roche Urisys	-	-	-	-	-	-	1	-	3	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	-	-	3	-	-
Thermo BioStar PocketChem UA	-	-	-	-	-	-	-	2	-	-	-
UriScan Reagent Strips	-	-	-	-	-	-	-	6	1	-	-

## URINALYSIS DIPSTICK–PROTEIN QUALITATIVE

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHOD	-	-	-	61	10	-
Arkray Aution Jet	-	-	-	2	-	-
Arkray Aution Sticks	-	-	-	2	-	-
Bayer Clinitek 50	-	-	-	-	3	-
Bayer Clinitek 500	-	-	-	14	-	-
Bayer Clinitek Atlas	-	-	-	3	1	-
Bayer Clinitek Status	-	-	-	-	1	-
Bayer Reagent Strips	-	-	-	2	2	-
Roche (BMC) Chemstrips	-	-	-	16	1	-
Roche (BMC) Criterion Analyzer	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	2	-	-
Roche Mditron	-	-	-	2	-	-
Roche Urisys	-	-	-	3	1	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	3	-	-
Thermo BioStar PocketChem UA	-	-	-	2	-	-
UriScan Reagent Strips	-	-	-	7	-	-

**URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE**

**Specimen UA-1**

<u>Method</u>	<i>Participant Results</i>							
	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>&gt;1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHOD	-	1	-	7	18	34	7	4
Arkray Aution Jet	-	-	-	-	-	-	1	1
Arkray Aution Sticks	-	-	-	-	-	1	1	-
Bayer Clinitek 50	-	-	-	1	1	-	1	-
Bayer Clinitek 500	-	-	-	5	10	-	-	-
Bayer Clinitek Atlas	-	-	-	-	3	-	1	-
Bayer Clinitek Status	-	-	-	1	-	-	-	-
Bayer Reagent Strips	-	-	-	-	3	1	-	-
Roche (BMC) Chemstrips	-	-	-	-	-	16	-	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	-	-	2	-	-
Roche Miditron	-	-	-	-	-	2	-	-
Roche Urisys	-	-	-	-	-	4	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	2	1	-
Thermo BioStar PocketChem UA	-	-	-	-	-	2	-	-
UriScan Reagent Strips	-	1	-	-	1	1	1	3

**URINALYSIS DIPSTICK–KETONES**

**Specimen UA-1**

<u>Method</u>	<i>Participant Results</i>				
	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHOD	-	-	-	3	68
Arkray Aution Jet	-	-	-	-	2
Arkray Aution Sticks	-	-	-	-	2
Bayer Clinitek 50	-	-	-	-	3
Bayer Clinitek 500	-	-	-	-	15
Bayer Clinitek Atlas	-	-	-	-	4
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	-	4
Roche (BMC) Chemstrips	-	-	-	1	16
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	2
Roche Miditron	-	-	-	1	1
Roche Urisys	-	-	-	-	4
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	3
Thermo BioStar PocketChem UA	-	-	-	-	1
UriScan Reagent Strips	-	-	-	1	6

## URINALYSIS DIPSTICK–BILIRUBIN

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHOD	72	-	-	-
Arkray Aution Jet	2	-	-	-
Arkray Aution Sticks	2	-	-	-
Bayer Clinitek 50	3	-	-	-
Bayer Clinitek 500	15	-	-	-
Bayer Clinitek Atlas	4	-	-	-
Bayer Clinitek Status	1	-	-	-
Bayer Reagent Strips	4	-	-	-
Roche (BMC) Chemstrips	17	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-
Roche (BMC) Mini UA	2	-	-	-
Roche Mditron	2	-	-	-
Roche Urisys	4	-	-	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-
UriScan Reagent Strips	7	-	-	-

## URINALYSIS DIPSTICK–UROBILINOGEN

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>&gt;8.0 mg/dL</u>
ALL METHOD	71	-	-	-	-
Arkray Aution Jet	2	-	-	-	-
Arkray Aution Sticks	2	-	-	-	-
Bayer Clinitek 50	3	-	-	-	-
Bayer Clinitek 500	15	-	-	-	-
Bayer Clinitek Atlas	4	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	3	-	-	-	-
Roche (BMC) Chemstrips	17	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Mditron	2	-	-	-	-
Roche Urisys	4	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-	-
UriScan Reagent Strips	7	-	-	-	-

**URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHOD	1	-	-	3	67
Arkray Aution Jet	1	-	-	-	1
Arkray Aution Sticks	-	-	-	1	1
Bayer Clinitek 50	-	-	-	-	3
Bayer Clinitek 500	-	-	-	-	14
Bayer Clinitek Atlas	-	-	-	-	4
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	-	4
Roche (BMC) Chemstrips	-	-	-	1	16
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	2
Roche Miditron	-	-	-	-	2
Roche Urisys	-	-	-	-	4
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	3
Thermo BioStar PocketChem UA	-	-	-	-	2
UriScan Reagent Strips	-	-	-	1	6

**URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHOD	68	-	-	-	1
Arkray Aution Jet	2	-	-	-	-
Arkray Aution Sticks	2	-	-	-	-
Bayer Clinitek 50	2	-	-	-	-
Bayer Clinitek 500	15	-	-	-	-
Bayer Clinitek Atlas	4	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	3	-	-	-	-
Roche (BMC) Chemstrips	17	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Miditron	2	-	-	-	-
Roche Urisys	4	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-	-
UriScan Reagent Strips	5	-	-	-	1

**URINALYSIS DIPSTICK–NITRITE**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHOD	69	-
Arkray Aution Jet	2	-
Arkray Aution Sticks	2	-
Bayer Clinitek 50	3	-
Bayer Clinitek 500	13	-
Bayer Clinitek Atlas	4	-
Bayer Clinitek Status	1	-
Bayer Reagent Strips	3	-
Roche (BMC) Chemstrips	17	-
Roche (BMC) Criterion Analyzer	3	-
Roche (BMC) Mini UA	2	-
Roche Mditron	2	-
Roche Urisys	4	-
Roche(BMC) SuperUA/ChemstripUA	3	-
Thermo BioStar PocketChem UA	2	-
UriScan Reagent Strips	7	-

**URINALYSIS –MICROALBUMIN (dipstick only)**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>10 mg/L(Pos)</u>	<u>20/30 mg/L</u>	<u>50 mg/L (+)</u>	<u>80 mg/L</u>	<u>100 mg/L (++)</u>	<u>150 mg/L</u>
ALL METHOD	-	-	-	-	-	-	2
Bayer Clinitek Microalbumin	-	-	-	-	-	-	1
Roche (BMC) Micral - 1 minute	-	-	-	-	-	-	1

**URINALYSIS –URINE hCG**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Sensitivity (mIU/mL)</u>	<u>Negative</u>	<u>Positive</u>
ALL METHOD	-	8	-
bioMerieux VIKIA hCG-D	25	6	-

**ANTIMICROBIAL SUSCEPTIBILITY TESTING**

**Specimen SUS-1**

<u>Antimicrobial</u>	-----Agar Diffusion-----				-----MIC-----				<u>Acceptable (%)</u>
	<u>Interpretative category data</u>				<u>Interpretative category data</u>				
	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	
Amikacin	5	5	-	-	17	17	-	-	100%
Amoxicillin/Clavulanate	3	2	1	-	9	9	-	-	92.9%
Ampicillin	6	6	-	-	18	17	-	1	97.2%
Ampicillin/Sulbactam	8	8	-	-	16	15	1	-	97.2%
Aztreonam	4	4	-	-	6	6	-	-	100%
Carbenicillin	1	1	-	-	-	-	-	-	100%
Cefaclor	2	2	-	-	1	-	1	-	Not graded <sup>1</sup>
Cefazolin	1	1	-	-	14	14	-	-	100%
Cefepime	1	1	-	-	6	6	-	-	100%
Cefixime	1	1	-	-	1	1	-	-	100%
Cefoperazone	1	1	-	-	-	-	-	-	100%
Cefotaxime	4	4	-	-	11	11	-	-	100%
Cefotetan	-	-	-	-	3	3	-	-	100%
Cefoxitin	2	2	-	-	1	-	1	-	90%
Cefpodoxime	-	-	-	-	1	1	-	-	100%
Ceftazidime	4	4	-	-	16	16	-	-	100%
Ceftizoxime	-	-	-	-	2	2	-	-	100%
Ceftriaxone	4	4	-	-	12	11	1	-	95.8%
Cefuroxime	3	3	-	-	10	9	-	1	95.8%
Cephalexin	1	1	-	-	-	-	-	-	100%
Cephalothin	8	7	1	-	13	12	1	-	Not graded <sup>1</sup>
Ciprofloxacin	9	9	-	-	18	18	-	-	100%
Clindamycin	1	-	-	1	-	-	-	-	100%
Gentamicin	8	8	-	-	20	20	-	-	100%
Imipenem	2	2	-	-	15	15	-	-	100%
Levofloxacin	-	-	-	-	11	11	-	-	100%
Meropenem	1	1	-	-	9	9	-	-	100%
Naldixic Acid	6	6	-	-	2	1	-	1	93.3%
Nitrofurantoin	12	11	1	-	19	18	1	-	95.7%
Norfloxacin	4	4	-	-	8	8	-	-	100%
Ofloxacin	1	1	-	-	2	2	-	-	100%
Piperacillin	-	-	-	-	9	8	1	-	93.8%
Piperacillin/Tazobactam	2	2	-	-	15	15	-	-	100%
Sulfamethoxazole	-	-	-	-	1	1	-	-	100%
Tetracycline	1	1	-	-	3	2	-	1	88.9%
Ticarcillin/Clavulanate	-	-	-	-	7	7	-	-	100%
Tobramycin	-	-	-	-	8	7	1	-	94.7%
Trimethoprim	1	1	-	-	2	1	-	1	Not graded <sup>1</sup>
Trimethoprim/Sulfamethoxazole	12	11	-	1	18	17	-	1	95.6%
Vancomycin	1	-	-	1	-	-	-	-	100%

Organism present in specimen SUS-1: *Escherichia coli*.

<sup>1</sup> This is an ungraded challenge due to less than 80% participant consensus.

## PARASITOLOGY (PA Specimens)

### Specimen PA-1

No participants reported PA-1.

Parasite present in specimen PA-1: *Entamoeba coli*.

### Specimen PA-2

No participants reported PA-2.

Parasite present in specimen PA-2: Negative for parasites.

### Specimen PA-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	1	100%	Unacceptable

Parasite present in specimen PA-13: *Entamoeba histolytica*.

### Specimen PA-4

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Taenia sp. eggs	1	100%	Acceptable

Parasite present in specimen PA-4: *Taenia sp. eggs*.

### Specimen PA-5

No participants reported PA-5.

Parasite present in specimen PA-5: *Plasmodium vivax*.

## PARASITOLOGY (FP Specimens)

### Specimen FP-1

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	61	49.19%	Acceptable
Trichuris trichiura eggs	51	41.13%	Acceptable
Hookworm	5	4.03%	
Entamoeba histolytica	2	1.61%	
Enterobius vermicularis eggs	1	0.81%	
Strongyloides stercoralis larvae	1	0.81%	
Blastocystis hominis	1	0.81%	
Endolimax nana	1	0.81%	
Microfilaris, sheathed, NOS	1	0.81%	

Parasites present in specimen FP-1: *Trichuris trichiura* eggs and *Ascaris lumbricoides* eggs.

### Specimen FP-2

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	50	78.13%	Acceptable
No parasite seen	6	9.38%	
Endolimax nana	3	4.69%	
Hookworm	1	1.56%	
Hymenolepis nana eggs	1	1.56%	
Taenia sp. eggs	1	1.56%	
Parasite larva seen but no ID	1	1.56%	
Blastocystis hominis	1	1.56%	

Parasite present in specimen FP-2: *Ascaris lumbricoides* eggs.

### Specimen FP-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Taenia sp. eggs	28	45.90%	Acceptable
No parasite seen	20	32.79%	
Entamoeba hartmanni	3	4.92%	
Hymenolepis nana eggs	2	3.28%	
Parasite larva seen but no ID	2	3.28%	
Ascaris lumbricoides eggs	2	3.28%	
Trichuris trichiura eggs	1	1.64%	
Strongyloides stercoralis larvae	1	1.64%	
Hookworm	1	1.64%	
Hymenolepis diminuta eggs	1	1.64%	

Parasite present in specimen FP-3: *Taenia* sp. eggs.

**PARASITOLOGY (FP Specimens)**

**Specimen FP-4**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Schistosoma mansoni eggs	6	8.70%	Acceptable
Schistosoma sp. eggs, NOS	2	2.90%	Acceptable
Blastocystis hominis	31	44.93%	
No parasite seen	16	23.19%	
Strongyloides stercoralis larvae	4	5.80%	
Fasciola hepatica eggs	3	4.35%	
Endolimax nana	2	2.90%	
Ascaris lumbricoides eggs	2	2.90%	
Taenia sp. eggs	1	1.45%	
Parasite larva seen but no ID	1	1.45%	
Schistosoma japonicum eggs	1	1.45%	

Parasite present in specimen FP-4: *Schistosoma mansoni* eggs.

**Specimen FP-5**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Plasmodium malariae	11	17.46%	Acceptable
Plasmodium sp., NOS	6	9.52%	Acceptable
Plasmodium sp., not falciparum	1	1.59%	Acceptable
Plasmodium vivax	34	53.97%	
Plasmodium ovale	5	7.94%	
Plasmodium falciparum	2	3.17%	
Babesia sp.	2	3.17%	
No parasite seen	2	3.17%	

Parasite present in specimen FP-5: *Plasmodium malariae*.

**Syphilis Serology—Qualitative: VDRL Slide**

<u>Method</u>	<u>Specimen SY-1</u>			<u>Specimen SY-2</u>			<u>Specimen SY-3</u>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	-	-	9	9	-	-	9	-	-
Becton Dickinson	-	-	1	1	-	-	1	-	-
BioBacter	-	-	3	3	-	-	3	-	-
SPINREACT	-	-	1	1	-	-	1	-	-
Wiener Lab	-	-	4	4	-	-	4	-	-

  

<u>Method</u>	<u>Specimen SY-4</u>			<u>Specimen SY-5</u>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	9	-	-	-	-	9
Becton Dickinson	1	-	-	-	-	1
BioBacter	3	-	-	-	-	3
SPINREACT	1	-	-	-	-	1
Wiener Lab	4	-	-	-	-	4

**Syphilis Serology—Quantitative: VDRL Slide Titer**

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>&gt;32 dils</u>
<b>Specimen SY-2</b>								
ALL METHOD	9	-	1	1	6	-	-	-
BioBacter	3	-	-	1	2	-	-	-
SPINREACT	1	-	-	-	1	-	-	-
Wiener Lab	4	-	1	-	2	-	-	-

<b>Specimen SY-3</b>								
ALL METHOD	8	1	1	5	1	-	-	-
BioBacter	3	1	-	2	-	-	-	-
SPINREACT	1	-	-	1	-	-	-	-
Wiener Lab	4	-	1	2	1	-	-	-

<b>Specimen SY-4</b>								
ALL METHOD	8	1	1	4	1	-	-	-
BioBacter	3	1	-	1	1	-	-	-
SPINREACT	1	-	-	1	-	-	-	-
Wiener Lab	4	-	1	2	-	-	-	-

**Syphilis Serology—Qualitative: MHA-TP**

<u>Method</u>	<u>Specimen SY-1</u>		<u>Specimen SY-2</u>		<u>Specimen SY-3</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	-	3	3	-	3	-
Serodia	-	1	1	-	1	-
<b>Specimen SY-4</b>						
ALL METHOD	3	-	-	3		
Serodia	1	-	-	1		
<b>Specimen SY-5</b>						
ALL METHOD	3	-	-	3		
Serodia	1	-	-	1		

**Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)**

<u>Method</u>	<u>Specimen SY-1</u>		<u>Specimen SY-2</u>		<u>Specimen SY-3</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	-	4	4	-	4	-
bioMerieux Vitek, Mini Vidas	-	1	1	-	1	-
<b>Specimen SY-4</b>						
ALL METHOD	4	-	-	4		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
<b>Specimen SY-5</b>						
ALL METHOD	4	-	-	4		
bioMerieux Vitek, Mini Vidas	1	-	-	1		

**Syphilis Serology—Qualitative: RPR**

<u>Method</u>	<u>Specimen SY-1</u>		<u>Specimen SY-2</u>		<u>Specimen SY-3</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	-	20	19	1	19	1
Abbott Syfacard-R	-	2	1	1	1	1
Becton Dickinson	-	1	1	-	1	-
bioMerieux Vitek, Mini Vidas	-	1	1	-	1	-
BioSystems	-	1	1	-	1	-
Immunostics Inc.	-	1	1	-	1	-
Omega Diagnostics	-	4	4	-	4	-
Serodia	-	1	1	-	1	-
SPINREACT	-	4	4	-	4	-

  

<u>Method</u>	<u>Specimen SY-4</u>		<u>Specimen SY-5</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHOD	19	1	-	20
Abbott Syfacard-R	1	1	-	2
Becton Dickinson	1	-	-	1
bioMerieux Vitek, Mini Vidas	1	-	-	1
BioSystems	1	-	-	1
Immunostics Inc.	1	-	-	4
Omega Diagnostics	4	-	-	1
Serodia	1	-	-	4
SPINREACT	4	-	-	20

**Syphilis Serology—Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>&gt;64</u>
<b>Specimen SY-2</b>								
ALL METHOD	-	4	9	-	1	-	-	1
Abbott Syfacard-R	-	-	1	-	-	-	-	-
bioMerieux Vitek, Mini Vidas	-	-	1	-	-	-	-	-
BioSystems	-	1	-	-	-	-	-	-
Omega Diagnostics	-	-	2	-	-	-	-	-
Serodia	-	-	-	-	-	-	-	1
SPINREACT	-	1	2	-	1	-	-	-
<b>Specimen SY-3</b>								
ALL METHOD	4	7	3	-	-	-	-	1
Abbott Syfacard-R	-	1	-	-	-	-	-	-
bioMerieux Vitek, Mini Vidas	-	1	-	-	-	-	-	-
BioSystems	1	-	-	-	-	-	-	-
Omega Diagnostics	-	1	1	-	-	-	-	-
Serodia	-	-	-	-	-	-	-	1
SPINREACT	1	1	2	-	-	-	-	-
<b>Specimen SY-4</b>								
ALL METHOD	4	8	2	-	-	-	-	1
Abbott Syfacard-R	-	1	-	-	-	-	-	-
bioMerieux Vitek, Mini Vidas	-	1	-	-	-	-	-	-
BioSystems	1	-	-	-	-	-	-	-
Omega Diagnostics	-	1	1	-	-	-	-	-
Serodia	-	-	-	-	-	-	-	1
SPINREACT	2	1	1	-	-	-	-	-

## Viral Markers – Anti-HBc

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	18	4	-	22	-	22
Abbott AxSYM	4	-	-	4	-	4
Abbott AxSYM - IgM	-	2	-	2	-	2
Abbott AxSYM - Total	4	-	-	4	-	4
Beckman ACCESS	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	1	-	1	-	1
Roche Cobas CORE	1	-	-	1	-	1
Roche Elecsys 1010/2010	2	-	-	2	-	2
Roche Modular Analytics	1	-	-	1	-	1
VITROS ECI	4	-	-	4	-	4
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHOD	16	6	17	5		
Abbott AxSYM	4	-	4	-		
Abbott AxSYM - IgM	-	2	-	2		
Abbott AxSYM - Total	3	1	3	1		
Beckman ACCESS	-	1	-	1		
bioMerieux Vidas - IgM	-	1	-	1		
Roche Cobas CORE	1	-	1	-		
Roche Elecsys 1010/2010	2	-	2	-		
Roche Modular Analytics	1	-	1	-		
VITROS ECI	3	1	4	-		

## Viral Markers – Anti-HIV

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	-	28	1	27	1	27
Abbott AxSYM	-	2	-	2	-	2
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	9	-	9	-	9
Bayer ADVIA Centaur	-	1	1	-	-	1
Beckman ACCESS	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	2	-	2	-	2
Roche Elecsys 1010/2010	-	6	-	6	-	6
VITROS ECI	-	2	-	2	-	2
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHOD	-	28	27	-		
Abbott AxSYM	-	2	2	-		
Abbott AxSYM - IgM	-	1	1	-		
Abbott AxSYM - Total	-	9	8	-		
Bayer ADVIA Centaur	-	1	1	-		
Beckman ACCESS	-	1	1	-		
bioMerieux Vidas - IgM	-	1	1	-		
bioMerieux Vitek, Mini Vidas	-	2	2	-		
Roche Elecsys 1010/2010	-	6	6	-		
VITROS ECI	-	2	2	-		

## Viral Markers – HAV

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	1	21	1	21	22	-
Abbott Architect	-	1	-	1	1	-
Abbott AxSYM	-	1	-	1	1	-
Abbott AxSYM - IgM	-	2	-	2	2	-
Abbott AxSYM - Total	-	5	-	5	5	-
bioMerieux Vidas - IgM	-	1	-	1	1	-
bioMerieux Vitek, Mini Vidas	-	3	-	3	3	-
Roche Elecsys 1010/2010	1	3	1	3	4	-
Roche Modular Analytics	-	1	-	1	1	-
VITROS ECI	-	2	-	2	2	-

  

<u>Method</u>	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	1	21	2	20
Abbott Architect	-	1	1	-
Abbott AxSYM	-	1	-	1
Abbott AxSYM - IgM	-	2	-	2
Abbott AxSYM - Total	-	5	-	5
bioMerieux Vidas - IgM	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	3	-	3
Roche Elecsys 1010/2010	1	3	1	3
Roche Modular Analytics	-	1	-	1
VITROS ECI	-	2	-	2

Specimen VM-1: Total is non-reactive.

Specimen VM-2: Total is non-reactive.

Specimen VM-3: Total and IgM are reactive.

Specimen VM-4: Total is non-reactive.

Specimen VM-5: Total is non-reactive.

## Viral Markers – HBeAg

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	-	11	-	11	-	11
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - Total	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	2	-	2	-	2
Roche Elecsys 1010/2010	-	2	-	2	-	2
VITROS ECI	-	2	-	2	-	2

  

<u>Method</u>	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	1	10	2	9
Abbott AxSYM	-	1	-	1
Abbott AxSYM - Total	-	1	1	-
bioMerieux Vitek, Mini Vidas	-	2	-	2
Roche Elecsys 1010/2010	-	2	-	2
VITROS ECI	1	1	1	1

## Viral Markers – HBsAb

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	-	27	-	27	-	27
Abbott Architect	-	1	-	1	-	1
Abbott AxSYM	-	5	-	5	-	5
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	4	-	4	-	4
Beckman ACCESS	-	1	-	1	-	1
Roche Elecsys 1010/2010	-	7	-	7	-	7
Roche Modular Analytics	-	1	-	1	-	1
VITROS Eci	-	4	-	4	-	4
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHOD	1	26	-	27		
Abbott Architect	-	1	-	1		
Abbott AxSYM	-	5	-	5		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	4	-	4		
Beckman ACCESS	1	-	-	1		
Roche Elecsys 1010/2010	-	7	-	7		
Roche Modular Analytics	-	1	-	1		
VITROS Eci	-	4	-	4		

## Viral Markers – Anti-HBsAg

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHOD	31	1	-	32	1	31
Abbott Architect	1	-	-	1	-	1
Abbott AxSYM	2	-	-	2	-	2
Abbott AxSYM - IgM	1	-	-	1	-	1
Abbott AxSYM - Total	8	-	-	8	-	8
Bayer ADVIA Centaur	-	1	-	1	1	-
Beckman ACCESS	1	-	-	1	-	1
bioMerieux Vitek, Mini Vidas	1	-	-	1	-	1
Roche Elecsys 1010/2010	7	-	-	7	-	7
VITROS Eci	5	-	-	5	-	5
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHOD	32	-	3	27		
Abbott Architect	1	-	-	1		
Abbott AxSYM	2	-	1	-		
Abbott AxSYM - IgM	1	-	-	1		
Abbott AxSYM - Total	8	-	1	6		
Bayer ADVIA Centaur	1	-	-	1		
Beckman ACCESS	1	-	-	1		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
Roche Elecsys 1010/2010	7	-	-	7		
VITROS Eci	5	-	1	4		

**Viral Markers – HCV**

<b><u>Method</u></b>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHOD	25	-	-	25	1	24
Abbott AxSYM	3	-	-	3	-	3
Abbott AxSYM - IgM	1	-	-	1	-	1
Abbott AxSYM - Total	5	-	-	5	-	5
Bayer ADVIA Centaur	1	-	-	1	1	-
bioMerieux Vitek, Mini Vidas	1	-	-	1	-	1
VITROS ECI	6	-	-	6	-	6
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHOD	-	25	9	16		
Abbott AxSYM	-	3	3	-		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	5	5	-		
Bayer ADVIA Centaur	-	1	-	1		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
VITROS ECI	-	6	-	6		

**Bilirubin, Total (mg/dL)**

<u>Reagent/Instrument</u>	<b>Specimen CH-1</b>					<b>Specimen CH-2</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method Beckman	13	3.38	0.70	20.8	3.1	13	0.88	0.17	18.9	0.9
All Chemistry Instruments	5	2.86	0.21	7.3	2.9	5	0.92	0.04	4.9	0.9
	<b>Specimen CH-3</b>					<b>Specimen CH-4</b>				
All Method Beckman	12	0.46	0.10	21.7	0.4	13	0.82	0.16	19.9	0.8
All Chemistry Instruments	5	2.54	4.51	177.4	0.6	5	0.98	0.04	4.6	1.0
	<b>Specimen CH-5</b>									
All Method Beckman	13	1.71	0.30	17.5	1.6					
All Chemistry Instruments	5	1.58	0.15	9.4	1.6					

**Neonatal Bilirubin, Total (mg/dL)**

<u>Reagent/Instrument</u>	<b>Specimen NB-1</b>					<b>Specimen NB-2</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method No Reagent Required	42	6.51	0.53	8.1	6.6	42	18.51	1.76	9.5	18.6
Advanced Bilirubin STAT-BR2	5	6.78	0.40	5.8	6.8	5	18.44	0.71	3.9	18.4
Bilirubinometer / Unistat	22	6.82	0.15	2.2	6.9	22	19.90	0.88	4.4	20.3
All Chemistry Instruments	27	6.80	0.27	4.0	6.8	27	19.24	1.08	5.6	19.2
VITROS - NBIL										
VITROS DT/DTII/DT60	13	6.08	0.37	6.1	6.0	13	17.28	1.80	10.4	17.7
All Chemistry Instruments	15	6.23	0.53	8.4	6.2	15	17.77	2.13	12.0	17.8
	<b>Specimen NB-3</b>					<b>Specimen NB-4</b>				
All Method No Reagent Required	42	2.50	0.30	11.9	2.5	42	11.69	1.28	11.0	11.8
Advanced Bilirubin STAT-BR2	5	2.80	0.07	2.5	2.8	5	12.24	0.59	4.8	12.2
Bilirubinometer / Unistat	22	2.22	0.10	4.4	2.3	22	12.70	0.69	5.4	13.2
All Chemistry Instruments	27	2.48	0.32	12.7	2.3	27	12.49	0.66	5.3	12.6
VITROS - NBIL										
VITROS DT/DTII/DT60	13	2.35	0.27	11.4	2.4	13	10.42	0.66	6.3	10.5
All Chemistry Instruments	15	2.40	0.29	12.1	2.4	15	10.85	1.28	11.8	10.6
	<b>Specimen NB-5</b>									
All Method No Reagent Required	39	20.74	1.68	8.1	20.6					
Advanced Bilirubin STAT-BR2	5	20.44	0.77	3.8	20.6					
Bilirubinometer / Unistat	22	22.43	1.38	6.2	22.5					
All Chemistry Instruments	27	21.53	1.51	7.0	21.3					
VITROS - NBIL										
VITROS DT/DTII/DT60	11	19.53	0.95	4.9	19.3					
All Chemistry Instruments	13	20.12	1.70	8.5	19.6					

## Blood Gases – pH

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	23	7.162	0.010	0.1	7.16	23	7.472	0.010	0.1	7.47
AVL OMNI	21	7.164	0.010	0.1	7.16	21	7.471	0.010	0.1	7.47
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	23	7.168	0.010	0.1	7.17	22	7.194	0.010	0.1	7.20
AVL OMNI	21	7.170	0.010	0.1	7.17	20	7.194	0.010	0.1	7.20
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	22	7.150	0.010	0.1	7.15					
AVL OMNI	20	7.150	0.010	0.1	7.15					

## Blood Gases - pCO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	22	71.21	2.10	3.0	71.2	21	19.24	0.93	4.8	19.3
AVL OMNI	20	71.17	2.11	3.0	71.2	20	19.42	1.28	6.6	19.4
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	22	58.26	1.51	2.6	58.3	22	47.57	1.14	2.4	47.6
AVL OMNI	20	58.22	1.56	2.7	58.3	20	47.59	1.19	2.5	47.6
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	22	73.42	1.82	2.5	73.7					
AVL OMNI	20	73.68	1.55	2.1	74.1					

## Blood Gases - pO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	23	72.77	8.53	11.7	74.2	22	110.73	7.98	7.2	110.8
AVL OMNI	21	73.60	8.46	11.5	74.4	19	108.66	5.74	5.3	110.0
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	22	112.89	6.26	5.5	114.0	21	138.67	5.49	4.0	139.0
AVL OMNI	20	112.52	6.43	5.7	113.3	19	138.04	5.36	3.9	137.4
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	23	75.10	10.68	14.2	75.1					
AVL OMNI	21	75.56	11.04	14.6	75.5					

## Blood Gases - Ionized Calcium (mmol/L)

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	2.054	1.559	75.9	1.47	7	1.570	1.244	79.2	1.09
AVL OMNI	6	2.145	1.688	78.7	1.47	6	1.638	1.348	82.3	1.09

**Blood Gases - Chloride (mmol/L)**

<u>Method</u>	Specimen BG-1					Specimen BG-1				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	79.8	5.5	6.9	79	9	97.0	2.9	3.0	96
AVL OMNI	7	79.9	5.9	7.4	78	8	97.1	3.0	3.1	97
Specimen BG-3										
All Method	9	88.3	4.2	4.8	88	9	76.7	4.0	5.3	76
AVL OMNI	8	88.1	4.5	5.1	88	8	76.4	4.2	5.5	76
Specimen BG-5										
All Method	8	78.5	5.7	7.2	77					
AVL OMNI	7	78.7	6.1	7.7	77					

**Blood Gases - Potassium (mmol/L)**

<u>Method</u>	Specimen BG-1					Specimen BG-1				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	9	1.78	0.14	7.9	1.7	9	5.59	0.11	1.9	5.6
AVL OMNI	8	1.75	0.12	6.8	1.7	8	5.59	0.11	2.0	5.6
Specimen BG-3										
All Method	9	3.16	0.10	3.2	3.1	9	2.19	0.09	4.2	2.2
AVL OMNI	8	3.15	0.11	3.4	3.1	8	2.18	0.09	4.1	2.2
Specimen BG-5										
All Method	9	1.73	0.12	7.1	1.7					
AVL OMNI	8	1.71	0.11	6.6	1.7					

**Blood Gases - Sodium (mmol/L)**

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	9	111.1	4.6	4.2	112	8	151.1	3.4	2.2	151
AVL OMNI	8	111.1	4.9	4.4	113	7	150.3	2.6	1.7	149
Specimen BG-3										
All Method	9	130.6	3.8	2.9	132	9	118.2	2.9	2.5	119
AVL OMNI	8	130.2	4.0	3.0	132	8	118.0	3.0	2.6	119
Specimen BG-5										
All Method	7	111.9	1.6	1.4	112					
AVL OMNI	6	112.2	1.5	1.3	113					

**Medical Laboratory Evaluation**

2011 Pennsylvania Avenue, NW, Suite 800

Washington, DC 20006-1813

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

[www.acponline.org/mle](http://www.acponline.org/mle)